Black Diamond Therapeutics (BDTX) Cash from Operations (2019 - 2021)
Historic Cash from Operations for Black Diamond Therapeutics (BDTX) over the last 3 years, with Q4 2021 value amounting to -$24.0 million.
- Black Diamond Therapeutics' Cash from Operations fell 5244.07% to -$24.0 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$100.1 million, marking a year-over-year decrease of 9205.31%. This contributed to the annual value of -$62.3 million for FY2024, which is 661.6% up from last year.
- Latest data reveals that Black Diamond Therapeutics reported Cash from Operations of -$24.0 million as of Q4 2021, which was down 5244.07% from -$26.5 million recorded in Q3 2021.
- Black Diamond Therapeutics' 5-year Cash from Operations high stood at -$5.0 million for Q2 2019, and its period low was -$26.5 million during Q3 2021.
- For the 3-year period, Black Diamond Therapeutics' Cash from Operations averaged around -$14.7 million, with its median value being -$12.5 million (2020).
- As far as peak fluctuations go, Black Diamond Therapeutics' Cash from Operations tumbled by 17134.0% in 2020, and later crashed by 5244.07% in 2021.
- Over the past 3 years, Black Diamond Therapeutics' Cash from Operations (Quarter) stood at -$7.5 million in 2019, then tumbled by 110.71% to -$15.8 million in 2020, then plummeted by 52.44% to -$24.0 million in 2021.
- Its Cash from Operations was -$24.0 million in Q4 2021, compared to -$26.5 million in Q3 2021 and -$25.2 million in Q2 2021.